Glenmark Pharmaceuticals Limited (GLENMARK.NS)
INR 1541.1
(1.08%)
INR 1541.1
(1.08%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -4.28 Billion INR | -113.46% |
| 2022 | 31.84 Billion INR | 24.8% |
| 2021 | 25.51 Billion INR | -33.69% |
| 2020 | 38.47 Billion INR | -5.6% |
| 2019 | 40.75 Billion INR | 16.04% |
| 2018 | 35.12 Billion INR | 3.12% |
| 2017 | 34.06 Billion INR | -7.12% |
| 2016 | 36.67 Billion INR | 17.13% |
| 2015 | 31.3 Billion INR | 3.12% |
| 2014 | 30.36 Billion INR | 22.81% |
| 2013 | 24.72 Billion INR | 14.47% |
| 2012 | 21.59 Billion INR | 12.22% |
| 2011 | 19.24 Billion INR | 0.4% |
| 2010 | 19.16 Billion INR | 8.76% |
| 2009 | 17.62 Billion INR | -12.88% |
| 2008 | 20.22 Billion INR | 142.42% |
| 2007 | 8.34 Billion INR | 0.42% |
| 2006 | 8.3 Billion INR | 31.94% |
| 2005 | 6.29 Billion INR | 103.03% |
| 2004 | 3.1 Billion INR | 190.59% |
| 2003 | 1.06 Billion INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | - INR | 100.0% |
| 2023 FY | -4.28 Billion INR | -113.46% |
| 2023 Q2 | 40.58 Billion INR | 176.16% |
| 2023 Q3 | 11.23 Billion INR | -72.31% |
| 2023 Q4 | -4.28 Billion INR | -138.13% |
| 2023 Q1 | 14.69 Billion INR | -53.84% |
| 2022 Q3 | 12.4 Billion INR | -58.67% |
| 2022 Q2 | 30 Billion INR | 112.58% |
| 2022 Q4 | 31.84 Billion INR | 156.78% |
| 2022 Q1 | 14.11 Billion INR | -44.68% |
| 2022 FY | 31.84 Billion INR | 24.8% |
| 2021 Q1 | 11.39 Billion INR | -70.39% |
| 2021 Q3 | 14.29 Billion INR | -42.08% |
| 2021 Q4 | 25.51 Billion INR | 78.47% |
| 2021 Q2 | 24.68 Billion INR | 116.67% |
| 2021 FY | 25.51 Billion INR | -33.69% |
| 2020 Q3 | 10.27 Billion INR | -50.37% |
| 2020 FY | 38.47 Billion INR | -5.6% |
| 2020 Q1 | 11.11 Billion INR | -72.73% |
| 2020 Q2 | 20.71 Billion INR | 86.4% |
| 2020 Q4 | 38.47 Billion INR | 274.31% |
| 2019 FY | 40.75 Billion INR | 16.04% |
| 2019 Q1 | 12.18 Billion INR | -65.32% |
| 2019 Q4 | 40.75 Billion INR | 255.84% |
| 2019 Q3 | 11.45 Billion INR | -56.0% |
| 2019 Q2 | 26.02 Billion INR | 113.7% |
| 2018 FY | 35.12 Billion INR | 3.12% |
| 2018 Q4 | 35.12 Billion INR | 103.28% |
| 2018 Q1 | 16.2 Billion INR | -52.43% |
| 2018 Q2 | 31.11 Billion INR | 92.03% |
| 2018 Q3 | 17.27 Billion INR | -44.47% |
| 2017 Q3 | 15.01 Billion INR | -52.29% |
| 2017 FY | 34.06 Billion INR | -7.12% |
| 2017 Q4 | 34.06 Billion INR | 126.83% |
| 2017 Q2 | 31.47 Billion INR | 197.96% |
| 2017 Q1 | 10.56 Billion INR | -71.2% |
| 2016 FY | 36.67 Billion INR | 17.13% |
| 2016 Q1 | 8.71 Billion INR | -72.16% |
| 2016 Q2 | 36.71 Billion INR | 321.12% |
| 2016 Q3 | 20.29 Billion INR | -44.73% |
| 2016 Q4 | 36.67 Billion INR | 80.72% |
| 2015 FY | 31.3 Billion INR | 3.12% |
| 2015 Q3 | 7.98 Billion INR | -67.46% |
| 2015 Q1 | 7.74 Billion INR | -74.49% |
| 2015 Q4 | 31.3 Billion INR | 292.04% |
| 2015 Q2 | 24.54 Billion INR | 216.92% |
| 2014 Q2 | 25.96 Billion INR | 220.75% |
| 2014 Q4 | 30.36 Billion INR | 592.74% |
| 2014 Q3 | 4.38 Billion INR | -83.12% |
| 2014 Q1 | 8.09 Billion INR | -67.25% |
| 2014 FY | 30.36 Billion INR | 22.81% |
| 2013 FY | 24.72 Billion INR | 14.47% |
| 2013 Q4 | 24.72 Billion INR | 144.65% |
| 2013 Q1 | 6.19 Billion INR | -71.32% |
| 2013 Q3 | 10.1 Billion INR | -55.79% |
| 2013 Q2 | 22.85 Billion INR | 269.0% |
| 2012 FY | 21.59 Billion INR | 12.22% |
| 2012 Q4 | 21.59 Billion INR | 554.09% |
| 2012 Q2 | -3.3 Billion INR | 0.0% |
| 2012 Q3 | 3.3 Billion INR | 200.0% |
| 2011 Q4 | 19.24 Billion INR | 0.0% |
| 2011 FY | 19.24 Billion INR | 0.4% |
| 2010 FY | 19.16 Billion INR | 8.76% |
| 2009 FY | 17.62 Billion INR | -12.88% |
| 2008 FY | 20.22 Billion INR | 142.42% |
| 2007 FY | 8.34 Billion INR | 0.42% |
| 2006 FY | 8.3 Billion INR | 31.94% |
| 2005 FY | 6.29 Billion INR | 103.03% |
| 2004 FY | 3.1 Billion INR | 190.59% |
| 2003 FY | 1.06 Billion INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Sigachi Industries Limited | 859.94 Million INR | 598.316% |
| Ind-Swift Limited | 9.5 Billion INR | 145.067% |
| Bajaj HealthCare Limited | 3.29 Billion INR | 229.897% |
| Sakar Healthcare Limited | 790.93 Million INR | 641.795% |
| Aurobindo Pharma Limited | 3.69 Billion INR | 216.028% |
| Innova Captab Limited | 2.33 Billion INR | 283.62% |
| Divi's Laboratories Limited | -39.77 Billion INR | 89.225% |
| AstraZeneca Pharma India Limited | -5.01 Billion INR | 14.508% |
| Morepen Laboratories Limited | -231.17 Million INR | -1753.695% |
| Mankind Pharma Limited | -1.74 Billion INR | -145.103% |
| Sequent Scientific Limited | 4.17 Billion INR | 202.552% |
| Wanbury Limited | 1.1 Billion INR | 487.499% |
| Laurus Labs Limited | 24.35 Billion INR | 117.593% |
| Nectar Lifesciences Limited | 6.15 Billion INR | 169.596% |
| Glenmark Life Sciences Limited | -2.84 Billion INR | -50.748% |
| Alembic Limited | 66.9 Million INR | 6505.471% |
| Hikal Limited | 7.96 Billion INR | 153.788% |
| Alembic Pharmaceuticals Limited | 3.86 Billion INR | 210.848% |
| Neuland Laboratories Limited | -214.05 Million INR | -1901.915% |
| J. B. Chemicals & Pharmaceuticals Limited | 2.82 Billion INR | 251.895% |
| IOL Chemicals and Pharmaceuticals Limited | -1.1 Billion INR | -289.109% |
| Themis Medicare Limited | 764.96 Million INR | 660.193% |
| RPG Life Sciences Limited | -364.7 Million INR | -1075.01% |
| Zydus Lifesciences Limited | 3.91 Billion INR | 209.541% |
| Lupin Limited | 19.38 Billion INR | 122.106% |
| Amrutanjan Health Care Limited | -248.79 Million INR | -1622.427% |
| Wockhardt Limited | 18.27 Billion INR | 123.455% |
| Vaishali Pharma Limited | 119.13 Million INR | 3696.978% |
| Aarti Pharmalabs Limited | 2.61 Billion INR | 264.067% |
| Jagsonpal Pharmaceuticals Limited | -1.38 Billion INR | -208.308% |
| Jubilant Pharmova Limited | 27.07 Billion INR | 115.829% |
| FDC Limited | -57.75 Million INR | -7320.107% |
| Dr. Reddy's Laboratories Limited | 12.91 Billion INR | 133.186% |
| Kilitch Drugs (India) Limited | 120.03 Million INR | 3669.89% |
| Eris Lifesciences Limited | 13.8 Billion INR | 131.038% |
| Venus Remedies Limited | -267.7 Million INR | -1500.77% |
| ZIM Laboratories Limited | 983.6 Million INR | 535.669% |
| Bliss GVS Pharma Limited | -1.15 Billion INR | -270.136% |
| Par Drugs and Chemicals Limited | -366.53 Million INR | -1069.114% |
| Caplin Point Laboratories Limited | -5.5 Billion INR | 22.195% |
| Shilpa Medicare Limited | 9.06 Billion INR | 147.249% |
| Albert David Limited | -278.36 Million INR | -1439.417% |
| Ajanta Pharma Limited | -954.9 Million INR | -348.765% |
| Hester Biosciences Limited | 2.29 Billion INR | 287.069% |
| Suven Pharmaceuticals Limited | 144.97 Million INR | 3055.841% |
| Solara Active Pharma Sciences Limited | 10.03 Billion INR | 142.717% |
| Gufic Biosciences Limited | 3.19 Billion INR | 234.153% |
| Windlas Biotech Limited | -273.04 Million INR | -1469.462% |
| Procter & Gamble Health Limited | -2.34 Billion INR | -82.507% |
| Aarey Drugs & Pharmaceuticals Limited | 297.57 Million INR | 1540.04% |
| Mangalam Drugs & Organics Limited | 975.81 Million INR | 539.149% |
| Granules India Limited | 9.28 Billion INR | 146.144% |
| Aarti Drugs Limited | 5.54 Billion INR | 177.234% |
| Bal Pharma Limited | 1.26 Billion INR | 439.142% |
| Alkem Laboratories Limited | -1.6 Billion INR | -166.264% |
| Sun Pharmaceutical Industries Limited | -72.47 Billion INR | 94.087% |
| Lincoln Pharmaceuticals Limited | -127.63 Million INR | -3257.354% |
| Medicamen Biotech Limited | 160.31 Million INR | 2773.008% |
| Unichem Laboratories Limited | 931.91 Million INR | 559.833% |
| Bafna Pharmaceuticals Limited | 229.93 Million INR | 1963.699% |
| Biofil Chemicals and Pharmaceuticals Limited | -18.44 Million INR | -23131.378% |
| Valiant Laboratories Limited | 649.9 Million INR | 759.37% |
| Orchid Pharma Limited | -1.31 Billion INR | -226.162% |
| Medico Remedies Limited | 78.67 Million INR | 5546.649% |
| Ind-Swift Laboratories Limited | -4.15 Billion INR | -3.183% |
| Ipca Laboratories Limited | 11.41 Billion INR | 137.54% |
| Brooks Laboratories Limited | 49.48 Million INR | 8759.715% |
| Syncom Formulations (India) Limited | 46.21 Million INR | 9373.247% |
| Piramal Enterprises Limited | 491.39 Billion INR | 100.872% |
| Torrent Pharmaceuticals Limited | 31.83 Billion INR | 113.463% |
| NATCO Pharma Limited | -5.81 Billion INR | 26.332% |
| Suven Life Sciences Limited | -1.63 Billion INR | -162.465% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | 321.699% |
| Strides Pharma Science Limited | 23.25 Billion INR | 118.426% |
| Indoco Remedies Limited | 6.47 Billion INR | 166.168% |
| Alpa Laboratories Limited | 35.36 Million INR | 12217.92% |
| Lasa Supergenerics Limited | 205.79 Million INR | 2182.255% |
| Sun Pharma Advanced Research Company Limited | -941.8 Million INR | -355.007% |